MUMBAI, India, June 22 -- Intellectual Property India has published a patent application (202631061753 A) filed by Mrinmoy Chakraborty; Baswant Patil; Shricharan Pandey; Suja Ram; and Suhani Sinha on May 15, 2026, for Intranasal Furosemide Nanoparticles For Enhanced Nose-To-Brain Drug Delivery.
Inventors include Mrinmoy Chakraborty; Baswant Patil; Shricharan Pandey; Suja Ram; and Suhani Sinha.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: The present invention relates to a pharmaceutical composition and method for formulating furosemide-loaded chitosan nanoparticles for intranasal nose-to-brain delivery. The method involves preparing a microemulsion of chitosan and furosemide using polysorbate 80 as a surfactant, followed by lyophilization and resuspension in phosphate-buffered saline to obtain a stable nanoparticle formulation suitable for administration. The invention provides a controlled and reproducible process for producing polymeric nanoparticles with uniform particle size, colloidal stability, and compatibility with nasal mucosa. The nanoparticles are designed for direct transport of furosemide to the central nervous system via the olfactory and trigeminal pathways, bypassing the blood-brain barrier. This approach offers a non-invasive and biocompatible platform for enhancing brain delivery of therapeutics, enabling potential applications in the treatment of neurological disorders such as Parkinson’s disease.
Disclaimer: Curated by HT Syndication.
